While retail chases an overleveraged AI bubble, Northwest Biotherapeutics just filed a Q3 10-Q that quietly checks off every major operational box across the US, the UK, and the courtroom:
I. US GMP Manufacturing Is Online for DCVax-L & Going Live for aDC1 in Q4
Instead of waiting on delayed university cleanroom leases, NWBO completed full tech transfer, engineering runs, and validation for DCVax-L with a contracted US manufacturer. They also transferred Dr. Pawel Kalinski aDC1 technology to the exact same US facility while training is complete, engineering runs are underway, and US aDC1 production will be fully operational this quarter (Q4).
II. Taking Direct Control of Clinical Trials + Harvard-Affiliated License
To bypass slow academic grant cycles and university personnel shifts, NWBO built and trained its own internal clinical operations team, completed SOPs and regulatory filings, and officially selected the target indication for its first Company-sponsored trial across its in-licensed portfolio which is now confirmed to include Roswell Park, Pittsburgh, and a Harvard-affiliated hospital.
III. US Compassionate Use & Commercial Rollout
Alongside active UK MHRA engagement and July's BNOS individual-patient analysis confirming substantially greater Phase III GBM survival extension, NWBO is partnering with NHSBT (Leeds and Oxford) and a private hospital chain to expand leukapheresis and cell processing, advancing its Saudi pharmaceutical MOU toward a definitive agreement, and actively arranging with several US hospitals to bring Compassionate Use to the United States.
IV. Blood in the Water in the Market-Maker Lawsuit
Fact discovery closed August 28. One lesser market-maker defendant has already agreed to a confidential settlement (funds in escrow while NWBO negotiates settlements with other lesser defendants). Meanwhile, the remaining defendants, including Citadel Securities and Virtu, are fighting in court over the order requiring them to hand over their proprietary trading algorithms.
V. Tighter Financial Discipline
Owning Advent Bioservices cut Q3 R&D expenses by 44% ($4.2M vs. $7.5M) and 9-month operating costs by $12.5M ($34.6M vs. $47.1M), while 9-month common stock issuance dropped 83% YoY ($3.0M vs. $17.3M), backed by a $2.25M Delaware settlement gain and a $1.0M interest-free loan from CEO Linda Powers.
Manufacturing validated in the US and UK, aDC1 scaling up, market makers settling, and SNO 2026 podium data dropping this weekend.
Let's go NWBO!


